71457
document
The SOFT trial : a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin ( SOX ) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer . A combination of oxaliplatin , leucovorin and 5-fluorouracil ( FOLFOX ) plus bevacizumab has been widely used for the first-line chemotherapy of metastatic colorectal cancer ( mCRC ) . S-1 is an oral fluoropyrimidine preparation that combines tegafur , a prodrug of 5-fluorouracil , with two modulators . Several studies of combination chemotherapy with oxaliplatin plus S-1 ( SOX ) conducted in Asia have reported promising efficacy and safety in patients with mCRC , suggesting the potential to replace mFOLFOX6 . The SOFT trial ( JapicCTI-090699 ) was a randomized Phase III trial designed to evaluate the noninferiority of SOX plus bevacizumab to mFOLFOX6 plus bevacizumab in patients with mCRC . This review summarizes the drug concept of S-1 and the results of clinical trials of S-1 and SOX in CRC and presents an overview of the SOFT trial .
71458
Intervention_Pharmacological
dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin ( SOX ) plus bevacizumab
71459
Intervention_Pharmacological
oxaliplatin , leucovorin and 5-fluorouracil ( FOLFOX ) plus bevacizumab
71460
Intervention_Physical
chemotherapy
71461
Intervention_Pharmacological
oxaliplatin plus S-1 ( SOX )
71462
Intervention_Pharmacological
mFOLFOX6
71463
Intervention_Pharmacological
SOX plus bevacizumab to mFOLFOX6 plus bevacizumab
71464
Intervention_Pharmacological
S-1 and SOX
71465
Outcome_Physical
evaluate the noninferiority of SOX
71466
Outcome_Physical
bevacizumab to mFOLFOX6 plus bevacizumab
71467
Outcome_Physical
mCRC
71468
Participant_Condition
metastatic colorectal cancer .
71469
Participant_Condition
metastatic colorectal cancer ( mCRC ) .
71470
Participant_Condition
patients with mCRC
71471
Participant_Condition
patients with mCRC